Notably, He et al. revealed fat mass and obesity‐associated protein (FTO)'s dual role as a demethylase of both m6A and m6Am,[8] while Suzuki et al.T identified PCIF1 as the writer of this modification.[9] Functional studies have unveiled diverse roles of m6Am under different biological contexts.[9, 10, 11] Emerging evidence also suggests its involvement in disease progression, including cancer, obesity, and viral infection,[12, 13, 14, 15] positioning m6Am as a potential therapeutic target in these disorders. The gene discussed is PCIF1; the disease is cancer.